repaglinide + insulin analogue

This drug is a **combination therapy** consisting of repaglinide, a meglitinide-class oral antidiabetic agent, and an insulin analogue. - **Repaglinide** is a fast-acting insulin secretagogue (meglitinide class) that stimulates **pancreatic β cells** to release insulin by inhibiting ATP-sensitive potassium channels in a glucose-dependent manner, thus enhancing the physiological insulin spike after meal ingestion[1][2][4]. - **Insulin analogues** are genetically engineered forms of insulin designed to mimic basal or prandial endogenous insulin more closely than human insulin, used for glycemic control in diabetes mellitus. Combining these agents targets both endogenous and exogenous insulin requirements to control postprandial and fasting blood glucose in **type 2 diabetes mellitus**. This approach is primarily used when oral therapy alone is insufficient for optimal glycemic control.